Search research articles
Contact Us
Filters
Showing results (1-10 of 66) with videos related to
Page
of 7
Sort By:
Advances in Therapy
|
August 23, 2014
Additional information regarding the SEVITENSION study
Luis Ruilope
Blood Pressure
|
April 21, 2017
Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade
Luis Ruilope
Advances in Therapy
|
December 3, 2013
The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
Luis Ruilope, Angie Schaefer
Expert Opinion on Pharmacotherapy
|
January 9, 2003
Eprosartan for the treatment of hypertension
Luis Ruilope, Bodo Jäger
Advances in Therapy
|
February 26, 2015
Erratum to: The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
Luis Ruilope, Angie Schaefer
F1000Research
|
May 23, 2017
The impact of antihypertensives on kidney disease
Diego F Marquez, Gema Ruiz-Hurtado, Luis Ruilope
Advances in Therapy
|
July 19, 2017
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Franck Boccara, Ricardo Dent, Luis Ruilope, et al.
Journal of the American Society of Hypertension : JASH
|
December 7, 2013
Review of blood pressure control rates and outcomes
George Bakris, Pantelis Sarafidis, Rajiv Agarwal, et al.
F1000Research
|
October 5, 2019
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Diego Francisco Márquez, Gema Ruiz-Hurtado, Julian Segura, et al.
Lancet (London, England)
|
August 18, 2017
Born to run: our future depends on it
Alejandro Santos-Lozano, Alejandro Lucia, Luis Ruilope, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 66) with videos related to
Sort By:
Page
of 7
Advances in Therapy
|
August 23, 2014
Additional information regarding the SEVITENSION study
Luis Ruilope
Blood Pressure
|
April 21, 2017
Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade
Luis Ruilope
Advances in Therapy
|
December 3, 2013
The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
Luis Ruilope, Angie Schaefer
Expert Opinion on Pharmacotherapy
|
January 9, 2003
Eprosartan for the treatment of hypertension
Luis Ruilope, Bodo Jäger
Advances in Therapy
|
February 26, 2015
Erratum to: The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
Luis Ruilope, Angie Schaefer
F1000Research
|
May 23, 2017
The impact of antihypertensives on kidney disease
Diego F Marquez, Gema Ruiz-Hurtado, Luis Ruilope
Advances in Therapy
|
July 19, 2017
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Franck Boccara, Ricardo Dent, Luis Ruilope, et al.
Journal of the American Society of Hypertension : JASH
|
December 7, 2013
Review of blood pressure control rates and outcomes
George Bakris, Pantelis Sarafidis, Rajiv Agarwal, et al.
F1000Research
|
October 5, 2019
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Diego Francisco Márquez, Gema Ruiz-Hurtado, Julian Segura, et al.
Lancet (London, England)
|
August 18, 2017
Born to run: our future depends on it
Alejandro Santos-Lozano, Alejandro Lucia, Luis Ruilope, et al.
Page
of 7